FORMULATION AND EVALUATION OF SOLID LIPID NANOPARTICLES OF BRIGATINIB

Treating human non-small cell lung cancer effectively remains a significant challenge due to issues, such as low absorption, frequent dosing, and side effects associated with traditional anti-cancer drugs. This study focuses at solid lipid nanoparticles (SLNs) as a new way to deliver drugs. These nanoparticles could provide better control over how these drugs are absorbed and released in the body, making treatment more manageable for patients. Brigatinib -loaded SLNs were prepared by modified high shear homogenization and ultrasonication method using different concentration of solid lipid (Compritol 888 ATO, Cholesterol) and stabilizers (Tween 80 or Span 20) The physicochemical properties and the in vitro release study for all Brigatinib -loaded SLNs were investigated. The results showed that Brigatinib loaded-SLNs were almost spherical shape having colloidal sizes with no aggregation. The drug entrapment efficiency ranged from 53.25% to near 76.18%. The zeta potential values lie between -25.3and -29.5mV presenting good stability. From the results F6 considered as optimized formulation. Keywords: Brigatinib and solid lipid nanoparticles.